Aspergillus fumigatus PCR is currently used in conjunction with serum galactomannan to support the diagnosis of invasive aspergillosis or for monitoring at-risk patients not receiving antifungal prophylaxis. A positive result and a high titer are thought to be associated with the advanced stage of the disease and the fungal load. However, there is limited data on this subject, and no study has primarily focused on the variation of PCR levels during treatment and its potential correlation with treatment efficacy.
Patients aged 18 years or older
Positive Aspergillus fumigatus PCR on serum or bronchoalveolar lavage fluid at diagnosis, performed at the Strasbourg University Hospital between January 1, 2017, and December 31, 2024.
No subsequent Aspergillus fumigatus PCR (>24h)
No diagnosis of probable or proven invasive aspergillosis (EORTC/MSGERC 2020 criteria)
Effective antifungal treatment against Aspergillus initiated before the first PCR
Death <72h after starting antifungal treatment
Major patient with positive Aspergillus fumigatus PCR on serum or bronchoalveolar lavage fluid at diagnosis, performed at the Strasbourg University Hospital between January 1, 2017, and December 31, 2024.
Case-only
Retrospective
Not listed
Death rate at day 30 in patients with a positive follow-up PCR (blood or bronchoalveolar lavage)
Death rate at day 30 in patients with a positive follow-up PCR (blood or bronchoalveolar lavage) after the start of treatment
Click on the lead sponsor to view all of their trials.
